drugset / Trial / NCT01655771

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01655771

Phase 1 Completed 47 enrolled Glycyx Therapeutics Theravance Biopharma · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.

Timeline

Start
2012-08
Primary completion
2013-02
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject axelopran Small molecule Oral

Indications